Home › NDC Lookup › Ingredients › Amoxicillin And Clavulanate Potassium › 76420-0529-20

Amoxicillin and Clavulanate Potassium 875 mg; 125 mg Tablet, Film Coated, 20-count

by Asclemed USA, Inc. · 20 TABLET, FILM COATED in 1 BOTTLE (76420-529-20)

NDC 76420-0529-20

🏷️ FDA NDC (as labeled) 76420-529-20 billing pads the product segment with a zero

Rx only Generic On market Non-controlled

🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm

📋 All sources & update times →

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 76420-529-20

Product NDC 76420-529

11-digit billing NDC 76420052920

NCPDP billing unit EA — each (per item)

RxCUI 562508

UNII 804826J2HU, Q42OMW3AT8

Application # ANDA065096

SPL Set ID f05a27dd-5ced-4f62-8a0c-548c3a033f5e

Established class (EPC) Penicillin-class Antibacterial; beta Lactamase Inhibitor

Mechanism of action beta Lactamase Inhibitors

Chemical class Penicillins

DEA schedule Non-controlled

Marketing category ANDA

Marketing status On market

FDA listing status Listed (active directory)

Marketing start 2002-10-31

Route ORAL

Dosage form TABLET, FILM COATED

Substance AMOXICILLIN; CLAVULANATE POTASSIUM

GCN Seq No 024668

GCN 67076

HICL code 003962

Ingredient (HICL) Amoxicillin/Potassium Clav

HIC1 code W

Therapeutic class — broad (HIC1) Anti-Infecting Agents

HIC2 code W1

Therapeutic class — intermediate (HIC2) Antibiotics

HIC3 code W1A

Therapeutic class — specific (HIC3) Penicillin Antibiotics

AHFS code 08:12.16.08

AHFS class Aminopenicillin Antibiotics

FDB label name AMOX-CLAV 875-125 MG TABLET

FDB brand name Amoxicillin-Clavulanate Potass

Legend status F — Federal legend — prescription drug or device

TE code (Orange Book) AB · RLD · RS

Why two NDCs? The FDA registers this code as 76420-529-20 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 76420-0529-20. Same drug, same package — only the format differs.

Where does this data come from?

Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the beta Lactamase Inhibitor class.

Pharmacologic class beta Lactamase Inhibitor

How it works beta Lactamase Inhibitors

Where does this data come from?

Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerAsclemed USA, Inc.

Application holderTEVA PHARMACEUTICALS USA INC

FDA applicationANDA065096 (ANDA)

Labeler code76420

First marketedOct 2002

Product typeHuman Prescription Drug

Portfolio652 products on file

🔎 All NDCs from Asclemed USA, Inc.

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).

Where does this data come from?

Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name AMOX-CLAV 875-125 MG TABLET Ingredient Amoxicillin/Potassium Clav

📖 What it is MedlinePlus · NLM

Amoxicillin and clavulanic acid is used to treat certain infections caused by bacteria, including infections of the ears, lungs, sinus, skin, and urinary tract. Amoxicillin is in a class of medications called penicillin-like antibiotics. It works by stopping the growth of bacteria. Clavulanic acid is in a class of medications called beta-lactamase inhibitors. It works by stopping bacteria from breaking down amoxicillin. Antibiotics will not work for colds, flu, or other viral infections. Using antibiotics when they are not needed increases your risk of getting an infection later that resists a...

Read the full MedlinePlus article ↗

📗 Our plain-language guide HelloPharmacist

This antibiotic is used for a range of common bacterial infections — ear infections, sinus infections, lower respiratory tract infections, skin infections, and urinary tract infect...
What infections does amoxicillin/clavulanate actually treat?
Taking it at the start of a meal is the best approach. Food doesn't affect amoxicillin much, but it does meaningfully improve how much clavulanate your body absorbs. More important...
Should I take this with food or on an empty stomach?

📖 Read our full Amoxicillin / Clavulanate guide →

Patient education

📘 MedlinePlus patient leaflet ↗

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →

Where does this data come from?

Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color white

ShapeOval

Imprint93;22;75

Size22 mm

ScoringScored — splits in 2

One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.

Where does this data come from?

Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

UNII 0VUT3PMY82
Hypromellose 2910 is a plant-derived thickening agent made from cellulose. In medicines, it forms protective coatings on tablets or capsules, controls how fast the drug releases, and thickens liquid formulations.
UNII 1IVH67816N
Hypromellose 2910 is a plant-derived cellulose compound used as a thickener and film-former in medicines. It helps control how quickly the medication dissolves and creates protective coatings on tablets or capsules.
UNII 0WZ8WG20P6
Hypromellose 2910 is a plant-based cellulose derivative that acts as a thickener, binder, and film-coating agent. It helps control how quickly the medicine dissolves and protects the tablet or capsule from moisture and light.
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
UNII VH2XOU12IE
Polydextrose is a synthetic polymer made from dextrose (sugar) that acts as a bulking agent and filler in medicines. It helps give tablets and capsules proper volume and texture while often adding slight sweetness.
UNII Q662QK8M3B
Polyethylene glycol 8000 is a synthetic polymer made from ethylene oxide. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and add bulk to the medicine.
UNII ETJ7Z6XBU4
Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
UNII 5856J3G2A2
A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.
UNII 15FIX9V2JP
Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.
UNII XHX3C3X673
Triacetin is a clear, oily liquid made from glycerin and acetic acid. It works as a plasticizer and solvent in medicines, helping soften coatings and improve how liquids mix together in formulations.

11 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?

Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?

No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.

Why might an inactive ingredient be missing?

Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.

Can inactive ingredients matter?

Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price system	Per each	Per package
Retail pharmacies payNADAC · weekly	Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo	No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026	$0.0932	$1.86 / 20 tablets

Where does this data come from?

NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

Product	Labeler	Pack	NADAC/unit	TE	Status	Price vs. this
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 00093-2275-34	Teva	20 tablets	$0.286	AB	Availability likely	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 00143-9249-20	Hikma	20 tablets	$0.286	AB	Availability likely	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 00781-1852-01	Sandoz	100 tablets	$0.286	AB	Availability likely	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 16714-0297-01	NorthStar	20 tablets	$0.286	AB	Availability likely	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 42571-0162-01	Micro	100 tablets	$0.286	AB	Availability likely	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 60687-0803-01	American	1 tablet	$0.286	AB	Availability likely	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 65862-0503-01	Aurobindo	100 tablets	$0.286	AB	Availability likely	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 81964-0221-14	USAntibiotics,	20 tablets	$0.286	AB	Availability likely	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 16714-0014-01	Northstar	20 tablets	$0.340	AB	Discontinued	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 43063-0077-03	PD-Rx	3 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 43063-0377-02	PD-Rx	2 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 45865-0227-20	Medsource	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 50090-0822-00	A-S	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 50090-1809-00	A-S	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 50090-3179-00	A-S	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 50090-4413-00	A-S	20 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 50090-6324-00	A-S	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 50090-7003-00	A-S	14 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 50090-7415-00	A-S	14 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 55289-0767-10	PD-Rx	10 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 63187-0014-14	Proficient	14 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 63187-0327-20	Proficient	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 63187-0488-14	Proficient	14 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 63629-4541-01	Bryant	14 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 63629-5847-01	Bryant	6 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 67046-0955-03	Coupler	30 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68071-2982-02	NuCare	20 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 68071-3402-03	NuCare	30 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68071-3822-03	NuCare	3 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68071-3842-02	NuCare	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68071-3860-02	NuCare	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68071-3864-04	NuCare	14 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68071-3866-03	NuCare	30 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 68071-4224-02	NuCare	20 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 68071-4549-03	NuCare	3 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68071-4586-03	NuCare	30 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68071-4967-02	NuCare	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68071-5026-04	NuCare	14 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68071-5057-03	NuCare	3 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68071-5065-03	NuCare	3 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68071-5295-03	NuCare	3 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 68788-7531-02	Preferred	20 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 68788-8307-02	Preferred	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68788-8836-02	Preferred	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 70518-2225-00	REMEDYREPACK	20 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 70518-2263-03	REMEDYREPACK	1 tablet	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 70518-3604-00	REMEDYREPACK	1 tablet	—	AB	Discontinued	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 70518-3624-00	REMEDYREPACK	1 tablet	—	AB	Discontinued	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 70518-3676-00	REMEDYREPACK	1 tablet	—	AB	Discontinued	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 70518-3967-00	REMEDYREPACK	28 tablets	—	AB	Discontinued	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 70518-4148-00	REMEDYREPACK	100 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 70518-4424-00	REMEDYREPACK	30 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 71205-0331-14	Proficient	14 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 71205-0651-10	Proficient	10 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 71205-0712-10	Proficient	10 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 71335-2787-01	Bryant	10 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 71335-2917-01	Bryant	100 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 71335-3138-01	Bryant	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 72162-2211-02	Bryant	20 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 72162-2434-01	Bryant	100 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 72789-0147-03	PD-Rx	3 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 72789-0253-20	PD-Rx	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 72789-0421-14	PD-Rx	14 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 72789-0456-14	PD-Rx	14 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 72789-0459-14	PD-Rx	14 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 73043-0006-20	Devatis,	20 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 76420-0005-20	Asclemed	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 76420-0501-20	Asclemed	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mgthis 76420-0529-20	Asclemed	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 76420-0607-01	Asclemed	100 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 125 mg/1; 875 mg 80425-0180-01	Advanced	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 80425-0279-01	Advanced	20 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 81964-0575-83	USAntibiotics,	180 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 82804-0060-20	Proficient	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 82804-0177-14	Proficient	14 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 82804-0201-20	Proficient	20 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 82868-0002-10	Northwind	10 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 82868-0067-14	Northwind	14 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 85766-0019-01	Sportpharm	100 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 85766-0078-01	Sportpharm	100 tablets	—	AB	FDA listed	—
Amoxicillin And Clavulanate Potassium 875 mg/1; 125 mg 85766-0171-14	Sportpharm	14 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68071-2751-02	NuCare	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 68788-4158-02	Preferred	20 tablets	—	AB	FDA listed	—
amoxicillin and clavulanate potassium 875 mg/1; 125 mg 62135-0092-20	Chartwell	20 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 72789-0585-28	PD-Rx	28 tablets	—	AB	FDA listed	—
Amoxicillin and Clavulanate Potassium 875 mg/1; 125 mg 85766-0268-01	Sportpharm	1 tablet	—	AB	FDA listed	—

About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.

Where does this data come from?

Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️

2002

On the market since

Oct 2002

📍

2026

Currently FDA-listed

24 years listed

🔓

Generic on the market

this product is a generic

✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?

Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Amoxicillin and clavulanate potassium — the ingredient across all brands.

Top reported reactions

Diarrhoea1,880

Drug Hypersensitivity1,818

Nausea1,435

Dyspnoea1,404

Pyrexia1,399

Fatigue1,280

Pneumonia1,191

Age at onset

Neonate22

Infant18

Child89

Adolescent65

Adult1,981

Elderly1,579

Reporter sex

Male · 43%

Female · 57%

Unknown · 0%

Serious outcomes

Hospitalization13,276

Death2,605

Life-threatening1,837

Disabling591

Reports over time (by year) — tap or hover for the count & year

Most recent year is provisional (FAERS lags ~3 months).

Where does this data come from?

Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDC	Description	Marketing start	Status
76420-0529-20 You're viewing this	20 TABLET, FILM COATED in 1 BOTTLE (76420-529-20)	2022-12-13	Active

🧭 About this NDC listing & data coverage

Finished prescription product

What data is (and isn’t) available for this NDC — tap to expand

NDC identity (package / product / labeler codes)	✓ Available
Labeler	✓ Available
Product & package description	✓ Available
Marketing category & status	✓ Available
Active ingredient / dosage form / route	✓ Available
FDA label (SPL via DailyMed)	✓ Available
Package photos	✓ Available
Inactive ingredients (structured)	✓ Available
NADAC pharmacy acquisition price (CMS)	— Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data	✓ Available
HCPCS J-code billing crosswalk	— Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD)	— Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.

“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?

The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.

Is the NDC printed on the package the same as the 11-digit billing NDC?

Yes, they identify this exact package in different formats. The FDA registers it as 76420-529-20, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 76420-0529-20, written without dashes as 76420052920. The Identity section at the top of this page lists every form of this code.

What do the three segments of this NDC mean?

In 76420-0529-20, the first segment (76420) is the labeler code FDA assigned to Asclemed USA, Inc.; the middle segment (0529) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (20) identifies this exact package size and type. Together they name one specific package of one specific product.

Is this package still being marketed?

Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Asclemed USA, Inc.. Listing status can change — the directory data on this page refreshes weekly.

Who lists this product with the FDA?

Asclemed USA, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.

Do I need a prescription for this product?

This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.

This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.

Where does this data come from?

Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.

🎯 Indications and Usage ⏱️ Dosage and Administration 💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 🤒 Adverse Reactions 🔄 Drug Interactions 👥 Use in Specific Populations 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 🧬 Mechanism of Action 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients

🎯 Indications and Usage ~1 min read ▾

1 INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium Tablets USP and other antibacterial drugs, Amoxicillin and Clavulanate Potassium Tablets USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Amoxicillin and Clavulanate Potassium Tablets USP are combination penicillin-class antibacterials and beta-lactamase inhibitors indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: Amoxicillin and Clavulanate Potassium Tablets USP are combination penicillin-class antibacterials and beta-lactamase inhibitors indicated for treatment of the following: Lower respiratory tract infections ( 1.1 ) Acute bacterial otitis media ( 1.2 ) Sinusitis ( 1.3 ) Skin and skin structure infections ( 1.4 ) Urinary tract infections ( 1.5 )

1.1Lower Respiratory Tract Infections – caused by beta-lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis .

1.2Acute Bacterial Otitis Media – caused by beta-lactamase–producing isolates of H. influenzae and M. catarrhalis .

1.3Sinusitis – caused by beta-lactamase–producing isolates of H. influenzae and M. catarrhalis .

1.4Skin and Skin Structure Infections – caused by beta-lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species.

1.5Urinary Tract Infections – caused by beta-lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species.

1.6Limitations of Use – When susceptibility test results show susceptibility to amoxicillin, USP, indicating no beta-lactamase production, Amoxicillin and Clavulanate Potassium Tablets USP, Amoxicillin and Clavulanate Potassium for Oral Suspension USP, and Amoxicillin and Clavulanate Potassium Tablets USP (Chewable) should not be used.

⏱️ Dosage and Administration ~3 min read ▾

2 DOSAGE AND ADMINISTRATION Amoxicillin and Clavulanate Potassium Tablets may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when Amoxicillin and Clavulanate Potassium Tablets are administered at the start of a meal. To minimize the potential for gastrointestinal intolerance, Amoxicillin and Clavulanate Potassium Tablets should be taken at the start of a meal. Adults and Pediatric Patients > 40 kg: 500 mg/125 mg or 875 mg/125 mg every 12 hours or 250 mg/125 mg or 500 mg/125 mg every 8 hours.

( 2.1 , 2.2 ) Pediatric Patients Aged 12 Weeks (3 Months) and Older: 25 to 45 mg/kg/day every 12 hours or 20 to 40 mg/kg/day every 8 hours, up to the adult dose. ( 2.2 )

2.1Adults The usual adult dose is one 500 mg/125 mg Amoxicillin and Clavulanate Potassium Tablet every 12 hours or one 250 mg/125 mg Amoxicillin and Clavulanate Potassium Tablet every 8 hours. For more severe infections and infections of the respiratory tract, the dose should be one 875 mg/125 mg Amoxicillin and Clavulanate Potassium Tablet every 12 hours or one 500 mg/125 mg Amoxicillin and Clavulanate Potassium Tablet every 8 hours. Adults who have difficulty swallowing may be given the 125 mg/31.25 mg per 5 mL or 250 mg/62.5 mg per 5 mL suspension in place of the 500 mg/125 mg tablet.

The 200 mg/28.5 mg per 5 mL suspension or the 400 mg/57 mg per 5 mL suspension may be used in place of the 875 mg/125 mg tablet. Two 250 mg/125 mg Amoxicillin and Clavulanate Potassium Tablets should not be substituted for one 500 mg/125 mg Amoxicillin and Clavulanate Potassium Tablet. Since both the 250 mg/125 mg and 500 mg/125 mg Amoxicillin and Clavulanate Potassium Tablets contain the same amount of clavulanic acid (125 mg, as the potassium salt), two 250 mg/125 mg tablets are not equivalent to one 500 mg/125 mg Amoxicillin and Clavulanate Potassium Tablet.

The 250 mg/125 mg Amoxicillin and Clavulanate Potassium Tablet and the 250 mg/62.5 mg chewable tablet should not be substituted for each other, as they are not interchangeable. The 250 mg/125 mg Amoxicillin and Clavulanate Potassium Tablet and the 250 mg/62.5 mg chewable tablet do not contain the same amount of clavulanic acid (as the potassium salt). The 250 mg/125 mg Amoxicillin and Clavulanate Potassium Tablet contains 125 mg of clavulanic acid, whereas the 250 mg/62.5 mg chewable tablet contains 62.5 mg of clavulanic acid.

2.2Pediatric Patients Patients Weighing 40 kg or More: Pediatric patients weighing 40 kg or more should be dosed according to adult recommendations. The 250 mg/125 mg Amoxicillin and Clavulanate Potassium Tablets should not be used until the child weighs at least 40 kg, due to the different amoxicillin to clavulanic acid ratios in the 250 mg/125 mg Amoxicillin and Clavulanate Potassium Tablets (250/125) versus the 250 mg/62.5 mg Amoxicillin and Clavulanate Potassium Tablets (Chewable) (250/62.5).

2.3Patients With Renal Impairment Patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe. Renal impairment patients with a glomerular filtration rate of < 30 mL/min should not receive the 875 mg/125 mg dose. Patients with a glomerular filtration rate of 10 to 30 mL/min should receive 500 mg/125 mg or 250 mg/125 mg every 12 hours, depending on the severity of the infection.

Patients with a glomerular filtration rate less than 10 mL/min should receive 500 mg/125 mg or 250 mg/125 mg every 24 hours, depending on severity of the infection. Hemodialysis patients should receive 500 mg/125 mg or 250 mg/125 mg every 24 hours, depending on severity of the infection. They should receive an additional dose both during and at the end of dialysis.

💊 Dosage Forms and Strengths 66 words ▾

3 DOSAGE FORMS AND STRENGTHS Tablets 875 mg/125 mg Tablets: White, capsule-shaped, biconvex, film-coated, scored tablets, debossed 93 on one side and 22 score line 75 on the other side. Each tablet contains 875 mg amoxicillin as the trihydrate and 125 mg clavulanic acid as the potassium salt. Formulations and amoxicillin/clavulanate content are: Tablets: 875 mg/125 mg; 875 mg/125 mg tablets are scored. ( 3 )

⛔ Contraindications 96 words ▾

4 CONTRAINDICATIONS History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin/clavulanate potassium or to other beta-lactams (e.g., penicillins or cephalosporins) ( 4 ) History of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate potassium. ( 4 )

4.1Serious Hypersensitivity Reactions Amoxicillin/clavulanate potassium is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin, clavulanate or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins).

4.2Cholestatic Jaundice/Hepatic Dysfunction Amoxicillin/clavulanate potassium is contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate potassium.

⚠️ Warnings and Cautions ~2 min read ▾

5 WARNINGS AND PRECAUTIONS Serious (including fatal) hypersensitivity reactions: Discontinue amoxicillin and clavulanate potassium tablets if a reaction occurs. ( 5.1 ) Hepatic dysfunction and cholestatic jaundice: Discontinue if signs/symptoms of hepatitis occur. Monitor liver function tests in patients with hepatic impairment.

( 5.2 ) Clostridium difficile -associated diarrhea (CDAD): Evaluate patients if diarrhea occurs. ( 5.3 ) Patients with mononucleosis who receive amoxicillin/clavulanate potassium develop skin rash. Avoid amoxicillin/clavulanate potassium use in these patients.

( 5.4 ) Overgrowth: The possibility of superinfections with fungal or bacterial pathogens should be considered during therapy. ( 5.5 )

5.1Hypersensitivity Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterials, including amoxicillin/clavulanate potassium. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. Before initiating therapy with amoxicillin and clavulanate potassium tablets, careful inquiry should be made regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens.

If an allergic reaction occurs, amoxicillin and clavulanate potassium tablets should be discontinued and appropriate therapy instituted.

5.2Hepatic Dysfunction Hepatic dysfunction, including hepatitis and cholestatic jaundice has been associated with the use of amoxicillin/clavulanate potassium. Hepatic toxicity is usually reversible; however, deaths have been reported. Hepatic function should be monitored at regular intervals in patients with hepatic impairment.

5.3Clostridium Difficile Associated Diarrhea (CDAD) Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including amoxicillin/clavulanate potassium, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD.

Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated.

5.4Skin Rash in Patients With Mononucleosis A high percentage of patients with mononucleosis who receive amoxicillin develop an erythematous skin rash. Thus, amoxicillin and clavulanate potassium tablets should not be administered to patients with mononucleosis.

5.5Potential for Microbial Overgrowth The possibility of superinfections with fungal or bacterial pathogens should be considered during therapy. If superinfection occurs, amoxicillin/clavulanate potassium should be discontinued and appropriate therapy instituted.

5.7Development of Drug-Resistant Bacteria Prescribing amoxicillin and clavulanate potassium tablets in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient, and increases the risk of the development of drug-resistant bacteria.

🤒 Adverse Reactions ~2 min read ▾

6 ADVERSE REACTIONS The following are discussed in more detail in other sections of the labeling: Anaphylactic reactions [see Warnings and Precautions ( 5.1 )] Hepatic Dysfunction [see Warnings and Precautions ( 5.2 )] CDAD [see Warnings and Precautions ( 5.3 )] The most frequently reported adverse effects were diarrhea/loose stools (9%), nausea (3%), skin rashes and urticaria (3%), vomiting (1%) and vaginitis (1%) ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals USA, Inc. at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most frequently reported adverse reactions were diarrhea/loose stools (9%), nausea (3%), skin rashes and urticaria (3%), vomiting (1%) and vaginitis (1%). Less than 3% of patients discontinued therapy because of drug-related adverse reactions.

The overall incidence of adverse reactions, and in particular diarrhea, increased with the higher recommended dose. Other less frequently reported adverse reactions (< 1%) include: Abdominal discomfort, flatulence, and headache. In pediatric patients (aged 2 months to 12 years), 1 U.S./Canadian clinical trial was conducted which compared 45/6.4 mg/kg/day (divided every 12 hours) of amoxicillin/clavulanate potassium for 10 days versus 40/10 mg/kg/day (divided every 8 hours) of amoxicillin/clavulanate potassium for 10 days in the treatment of acute otitis media.

A total of 575 patients were enrolled, and only the suspension formulations were used in this trial. Overall, the adverse reactions seen were comparable to that noted above; however, there were differences in the rates of diarrhea, skin rashes/urticaria, and diaper area rashes. [See Clinical Studies ( 14.2 )]

6.2Postmarketing Experience In addition to adverse reactions reported from clinical trials, the following have been identified during postmarketing use of amoxicillin/clavulanate potassium. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to amoxicillin/clavulanate potassium.

Gastrointestinal: Indigestion, gastritis, stomatitis, glossitis, black “hairy” tongue, mucocutaneous candidiasis, enterocolitis, and hemorrhagic/pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment. [see Warnings and Precautions ( 5.3 )] Hypersensitivity Reactions: Pruritus, angioedema, serum sickness–like reactions (urticaria or skin rash accompanied by arthritis, arthralgia, myalgia, and frequently fever), erythema multiforme, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, hypersensitivity vasculitis, and cases of exfoliative dermatitis (including toxic epidermal necrolysis) have been reported. [see Warnings and Precautions ( 5.1 )] Liver: Hepatic dysfunction, including hepatitis and cholestatic jaundice, increases in serum transaminases (AST and/or ALT), serum bilirubin, and/or alkaline phosphatase, has been reported with amoxicillin/clavulanate potassium.

It has been reported more commonly in the elderly, in males, or in patients on prolonged treatment. The histologic findings on liver biopsy have consisted of predominantly cholestatic, hepatocellular, or mixed cholestatic-hepatocellular changes. The onset of signs/symptoms of hepatic dysfunction may occur during or several weeks after therapy has been discontinued.

The hepatic dysfunction, which may be severe, is usually reversible. Deaths have been reported. [see Contraindications ( 4.2 ), Warnings and Precautions ( 5.2 )] Renal: Interstitial nephritis, hem…

🔄 Drug Interactions ~1 min read ▾

7 DRUG INTERACTIONS Coadministration with probenecid is not recommended. ( 7.1 ) Concomitant use of amoxicillin/clavulanate potassium and oral anticoagulants may increase the prolongation of prothrombin time. ( 7.2 ) Coadministration with allopurinol increases the risk of rash. ( 7.3 ) Amoxicillin/clavulanate potassium may reduce efficacy of oral contraceptives. ( 7.4 )

7.1Probenecid Probenecid decreases the renal tubular secretion of amoxicillin but does not delay renal excretion of clavulanic acid. Concurrent use with amoxicillin/clavulanate potassium may result in increased and prolonged blood concentrations of amoxicillin. Coadministration of probenecid is not recommended.

7.2Oral Anticoagulants Abnormal prolongation of prothrombin time (increased international normalized ratio [INR]) has been reported in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently with amoxicillin/clavulanate potassium. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation.

7.3Allopurinol The concurrent administration of allopurinol and amoxicillin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving amoxicillin alone. It is not known whether this potentiation of amoxicillin rashes is due to allopurinol or the hyperuricemia present in these patients.

7.4Oral Contraceptives Amoxicillin/clavulanate potassium may affect intestinal flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.

7.5Effects on Laboratory Tests High urine concentrations of amoxicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST ® , Benedict’s Solution, or Fehling’s Solution. Since this effect may also occur with amoxicillin/clavulanate potassium, it is recommended that glucose tests based on enzymatic glucose oxidase reactions be used. Following administration of amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS Pediatric Use: Modify dose in patients 12 weeks or younger. ( 8.4 ) Renal Impairment; Dosage adjustment is recommended for severe renal impairment (GFR< 30 mL/min). ( 2.3 , 8.6 )

8.1Pregnancy Teratogenic Effects Pregnancy Category B Reproduction studies performed in pregnant rats and mice given amoxicillin/clavulanate potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses up to 1200 mg/kg/day revealed no evidence of harm to the fetus due to amoxicillin/clavulanate potassium. The amoxicillin doses in rats and mice (based on body surface area) were approximately 4 and 2 times the maximum recommended adult human oral dose (875 mg/125 mg every 12 hours). For clavulanate, these dose multiples were approximately 9 and 4 times the maximum recommended adult human oral dose (125 mg every 8 hours).

There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

8.2Labor and Delivery Oral ampicillin-class antibiotics are poorly absorbed during labor. It is not known whether use of amoxicillin/clavulanate potassium in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood of the necessity for an obstetrical intervention.

8.3Nursing Mothers Amoxicillin has been shown to be excreted in human milk. Amoxicillin/clavulanate potassium use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin/clavulanate potassium is administered to a nursing woman.

8.4Pediatric Use The safety and effectiveness of amoxicillin and clavulanate potassium for oral suspension and amoxicillin and clavulanate potassium tablets (chewable) have been established in pediatric patients. Use of amoxicillin and clavulanate potassium for oral suspension and amoxicillin and clavulanate potassium tablets (chewable) in pediatric patients is supported by evidence from studies of amoxicillin and clavulanate potassium tablets in adults with additional data from a study of amoxicillin and clavulanate potassium for oral suspension in pediatric patients aged 2 months to 12 years with acute otitis media. [ see Clinical Studies ( 14.2 ) ] Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed; clavulanate elimination is unaltered in this age group.

Dosing of amoxicillin and clavulanate potassium for oral suspension and amoxicillin and clavulanate potassium tablets (chewable) should be modified in pediatric patients aged < 12 weeks (< 3 months). [ see Dosage and Administration ( 2.2 ) ]

8.5Geriatric Use Of the 3,119 patients in an analysis of clinical studies of amoxicillin/clavulanate potassium, 32% were ≥ 65 years old, and 14% were ≥ 75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function.

Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

8.6Dosing in Renal Impairment Amoxicillin is primarily eliminated by the kidney and dosage adjustment is usually required in patients with severe renal impairment (GFR < 30 mL/min). See Patients With Renal Impairment ( 2.3 ) for specific recommendations in patients with renal impairment.

🤰 Pregnancy 129 words ▾

🧒 Pediatric Use 160 words ▾

🧓 Geriatric Use 128 words ▾

Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

🆘 Overdosage 153 words ▾

10 OVERDOSAGE In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms 1 . Interstitial nephritis resulting in oliguric renal failure has been reported in patients after overdosage with amoxicillin/clavulanate potassium.

Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin/clavulanate potassium overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin/clavulanate potassium crystalluria. Renal impairment appears to be reversible with cessation of drug administration.

High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of amoxicillin/clavulanate potassium. Amoxicillin/clavulanate potassium may be removed from circulation by hemodialysis. [see Dosage and Administration ( 2.3 ) ]

🧬 Clinical Pharmacology ~3 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Amoxicillin and clavulanate potassium tablets are antibacterial drugs. [see Microbiology 12.4 ]

12.3Pharmacokinetics Mean amoxicillin and clavulanate potassium pharmacokinetic parameters in normal adults following administration of amoxicillin and clavulanate potassium tablets are shown in Table 3 and following administration of amoxicillin and clavulanate potassium for oral suspension and chewable tablets are shown in Table 4 . Table 3: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters Mean (± standard deviation) values of 14 normal adults (N = 15 for clavulanate potassium in the low-dose regimens).

Peak concentrations occurred approximately 1.5 hours after the dose. Amoxicillin/clavulanate potassium administered at the start of a light meal. With Amoxicillin and Clavulanate Potassium Tablets Dose and Regimen C max (mcg/mL) AUC 0 to 24 (mcg*h/mL) Amoxicillin/Clavulanate Potassium Amoxicillin Clavulanate Potassium Amoxicillin Clavulanate Potassium 250 mg/125 mg every 8 hours 3.3 ± 1.12 1.5 ± 0.70 26.7 ± 4.56 12.6 ± 3.25 500 mg/125 mg every 12 hours 6.5 ± 1.41 1.8 ± 0.61 33.4 ± 6.76 8.6 ± 1.95 500 mg/125 mg every 8 hours 7.2 ± 2.26 2.4 ± 0.83 53.4 ± 8.87 15.7 ± 3.86 875 mg/125 mg every 12 hours 11.6 ± 2.78 2.2 ± 0.99 53.5 ± 12.31 10.2 ±

3.04Table 4: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters Mean ( ± standard deviation) values of 28 normal adults. Peak concentrations occurred approximately 1 hour after the dose. Amoxicillin/clavulanate potassium administered at the start of a light meal.

With Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets Dose C max (mcg/mL) AUC 0 to 24 (mcg*h/mL) Amoxicillin/Clavulanate Potassium Amoxicillin Clavulanate Potassium Amoxicillin Clavulanate Potassium 400 mg/57 mg (5 mL of suspension) 6.94 ± 1.24 1.10 ± 0.42 17.29 ± 2.28 2.34 ± 0.94 400 mg/57 mg (1 chewable tablet) 6.67 ± 1.37 1.03 ± 0.33 17.24 ± 2.64 2.17 ±

0.73Oral administration of 5 mL of 250 mg/62.5 mg per 5 mL suspension of amoxicillin/clavulanate potassium or the equivalent dose of 10 mL of 125 mg/31.25 mg per 5 mL suspension of amoxicillin/clavulanate potassium provides average peak serum concentrations approximately 1 hour after dosing of 6.9 mcg/mL for amoxicillin and 1.6 mcg/mL for clavulanic acid. The areas under the serum concentration curves obtained during the first 4 hours after dosing were 12.6 mcg*h/mL for amoxicillin and 2.9 mcg*h/mL for clavulanic acid when 5 mL of 250 mg/62.5 mg per 5 mL suspension of amoxicillin/clavulanate potassium or equivalent dose of 10 mL of 125 mg/31.25 mg per 5 mL suspension of amoxicillin/clavulanate potassium were administered to normal adults.

One 250 mg/62.5 mg chewable tablet of amoxicillin/clavulanate potassium or two 125 mg/31.25 mg chewable tablets of amoxicillin/clavulanate potassium are equivalent to 5 mL of 250 mg/62.5 mg per 5 mL suspension of amoxicillin/clavulanate potassium and provide similar serum concentrations of amoxicillin and clavulanic acid. Amoxicillin serum concentrations achieved with amoxicillin/clavulanate potassium are similar to those produced by the oral administration of equivalent doses of amoxicillin alone. Time above the minimum inhibitory concentration of 1 mcg/mL for amoxicillin has been shown to be similar after corresponding every 12 hour and every 8 hour dosing regimens of amoxicillin/clavulanate potassium in adults and children.

Absorption Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin. While amoxicillin/clavulanate potassium can be given without regard to meals, absorption of clavulanate potassium when taken with food is greater relative to the fasted state. In one study, the relative bioavailability of clavulanate was reduced when amoxicillin/clavulanate potassium was dosed at 30 and 150 minutes after the start of a high-fat breakfast.

Distribution Neither component in a…

🧬 Mechanism of Action 16 words ▾

12.1Mechanism of Action Amoxicillin and clavulanate potassium tablets are antibacterial drugs. [see Microbiology 12.4 ]

📦 How Supplied / Storage and Handling 126 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING Amoxicillin and Clavulanate Potassium Tablets USP Amoxicillin and Clavulanate Potassium Tablets USP are supplied as follows: 875 mg/125 mg: White, capsule-shaped, biconvex, film-coated, scored tablets, debossed 93 on one side and 22 score line 75 on the other side. Each tablet contains 875 mg amoxicillin, USP as the trihydrate and 125 mg clavulanic acid as the potassium salt. They are available in bottles of 20 tablets (NDC 76420-229-20 relabeled from NDC 0093-2275-34).

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). Advise patients to keep in a closed container.

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

📋 Description 207 words ▾

11 DESCRIPTION Amoxicillin and Clavulanate Potassium Tablets are oral antibacterial combinations consisting of the semisynthetic antibiotic amoxicillin, USP and the beta-lactamase inhibitor, clavulanate potassium, USP (the potassium salt of clavulanic acid). Amoxicillin, USP is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid. Chemically, amoxicillin, USP is ( 2S , 5R , 6R )-6-[( R )-(-)-2-Amino-2-( p -hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate and has the following structural formula: C 16 H 19 N 3 O 5 S•3H 2 O M.W.

419.45 Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus. It is a beta-lactam structurally related to the penicillins and possesses the ability to inactivate some beta-lactamases by blocking the active sites of these enzymes. Chemically, clavulanate potassium, USP is potassium ( Z )-(2 R ,5 R )-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate, and has the following structural formula: C 8 H 8 KNO 5 M.W.

237.25 Amoxicillin and Clavulanate Potassium Tablets USP Each tablet contains 875 mg amoxicillin, USP as the trihydrate and 125 mg clavulanic acid as the potassium salt. Each Amoxicillin and Clavulanate Potassium Tablet USP contains 0.63 mEq potassium. Inactive Ingredients: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium starch glycolate, titanium dioxide, and triacetin. amoxicillin structural formula clavulanic acid structural formula

💬 Information for Patients ~1 min read ▾

17 PATIENT COUNSELING INFORMATION

17.1Information for Patients Patients should be informed that amoxicillin and clavulanate potassium tablets may be taken every 8 hours or every 12 hours, depending on the dose prescribed. Each dose should be taken with a meal or snack to reduce the possibility of gastrointestinal upset. Patients should be counseled that antibacterial drugs, including amoxicillin and clavulanate potassium tablets, should only be used to treat bacterial infections.

They do not treat viral infections (e.g., the common cold). When amoxicillin and clavulanate potassium tablets are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by amoxicillin and clavulanate potassium tablets, amoxicillin or other antibacterial drugs in the future.

Counsel patients that diarrhea is a common problem caused by antibacterials, and it usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken their last dose of the antibacterial. If diarrhea is severe or lasts more than 2 or 3 days, patients should contact their physician.

Patients should be aware that amoxicillin and clavulanate potassium tablets contain a penicillin class drug product that can cause allergic reactions in some individuals. All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA. Relabeled by: Enovachem PHARMACEUTICALS Torrance, CA 90501

Glossary — plain-language definitions of medical terms used in this label:

contraindicated: Should not be used in that situation, because the risk is considered too high.

Absorption: How a medicine moves from where it is taken, such as the stomach or gut, into the bloodstream.

adverse reaction: An unwanted or harmful effect that a medicine causes in the body.

Adverse Reactions: Unwanted or harmful effects that people experienced while taking a medicine, listed on its official label.

alkaline phosphatase: An enzyme measured in a blood test; higher levels can point to problems with the liver, bile ducts, or bones.

ALT: A liver enzyme (alanine aminotransferase) checked by a blood test; raised levels can signal that the liver is irritated or damaged.

anaphylaxis: A sudden, severe, whole-body allergic reaction that can cause trouble breathing, swelling, and a drop in blood pressure, needing emergency care.

angioedema: Rapid swelling deep under the skin, often around the eyes, lips, tongue, or throat.

animal reproduction studies: Tests in pregnant animals used to check whether a medicine might harm a developing baby.

arthralgia: Joint pain.

AST: A liver enzyme (aspartate aminotransferase) measured in a blood test; higher levels may point to liver or sometimes muscle injury.

AUC: A measure of total drug exposure over time, showing how much medicine the blood is exposed to overall.

bilirubin: A yellow substance the liver normally clears from the blood; high levels can turn the skin or the whites of the eyes yellow.

Bioavailability: The share of a dose that actually reaches the bloodstream and is able to have an effect.

candidiasis: An infection caused by a yeast called Candida, which can affect the mouth, throat, skin, or other areas.

clearance: How quickly the body removes a medicine from the blood, usually through the liver and kidneys.

Clinical Pharmacology: The label section explaining how a medicine works in the body and how the body processes it.

Clinical Studies: The label section summarizing the research trials used to show that a medicine works and is acceptably safe.

colitis: Swelling and irritation of the inner lining of the large intestine, or colon.

Contraindications: A list of situations or health conditions in which a medicine should not be used because the chance of harm is too high.

dermatitis: Inflammation of the skin, causing redness, itching, and sometimes swelling or blisters.

diarrhea: Loose, watery bowel movements that happen more often than normal.

Distribution: How a medicine spreads from the blood into the body's tissues and organs after it is absorbed.

Dosage and Administration: The label section explaining how much of a medicine to use and how to take or give it.

Drug Interactions: The label section listing other medicines, foods, or substances that can change how a medicine works or raise the chance of side effects.

efficacy: How well a treatment works under the controlled conditions of a clinical study.

electrolyte: A mineral in the blood and body fluids, such as sodium, potassium, or calcium, that carries a small electric charge and helps the body work.

Elimination: The overall removal of a medicine from the body by breaking it down and passing it out.

erythema: Redness of the skin caused by increased blood flow, often from irritation or inflammation.

erythema multiforme: A skin reaction with red, target-shaped spots, usually on the hands, arms, or face.

Excretion: How the body removes a medicine or its leftover pieces, mainly through the urine or stool.

exfoliative dermatitis: Widespread redness with heavy scaling or peeling of the skin over most of the body.

flatulence: Passing gas from the bowel; feeling bloated or gassy.

gastritis: Swelling or irritation of the lining of the stomach.

GFR: A measure (glomerular filtration rate) of how well the kidneys filter the blood; lower numbers mean weaker kidney function.

hemodialysis: A treatment that uses a machine to filter waste and extra fluid from the blood when the kidneys cannot.

hepatic impairment: Reduced liver function, meaning the liver does not work as well as normal at processing substances, including medicines.

hepatitis: Inflammation of the liver, which can be caused by infections, alcohol, or certain medicines.

How Supplied/Storage and Handling: The label section describing the forms and strengths a medicine comes in and how to store it properly.

hypersensitivity: An overreaction of the body's defense system to a substance, causing symptoms such as rash, swelling, or trouble breathing.

hyperuricemia: A higher-than-normal level of uric acid in the blood, which can lead to gout.

incidence: How often a new event, such as a side effect, happens in a group of people over a set period of time.

Indications and Usage: The label section stating which medical conditions the FDA has officially approved the medicine to treat, prevent, or manage.

inhibitor: A substance that blocks an enzyme or transporter, which can raise the levels of drugs it normally handles.

INR: A blood test result that shows how quickly blood clots, often used to monitor blood-thinning medicines.

interstitial nephritis: Inflammation of the tissue between the kidney's tiny filtering tubes, sometimes triggered by a medicine, that can reduce kidney function.

jaundice: Yellowing of the skin and the whites of the eyes caused by too much bilirubin in the blood.

liver function tests: Blood tests that check how well the liver is working and whether it is irritated or damaged.

Mechanism of Action: How a medicine produces its effect in the body, described at the level of cells or body chemistry.

mucocutaneous: Involving both the skin and the moist linings of the body, such as the mouth, eyes, or nose.

myalgia: Muscle pain or aching.

NDC: A unique number that identifies a specific medicine, its maker, strength, and package size.

Overdosage: The label section describing what can happen if too much of a medicine is taken and how it may be treated.

Patient Counseling Information: The label section telling health professionals what to explain to patients about using a medicine safely.

Pharmacokinetics: The study of how the body takes in a medicine, spreads it around, breaks it down, and removes it over time.

plasma concentration: The amount of medicine measured in the liquid part of the blood at a given time.

pregnancy category: An older letter rating (A, B, C, D, or X) once used to describe a medicine's possible risk during pregnancy.

prothrombin time: A blood test that measures how many seconds it takes for blood to form a clot.

pruritus: Itching of the skin.

pseudomembranous colitis: A serious swelling of the large intestine, usually caused by C. difficile bacteria, that leads to severe diarrhea.

refractory: Describing a disease that does not respond to, or improve with, treatment.

renal excretion: Removal of a medicine from the body through the kidneys into the urine.

renal impairment: Reduced kidney function, meaning the kidneys do not filter waste and fluid from the blood as well as normal.

serum sickness: A delayed reaction, usually one to two weeks after exposure, causing fever, rash, and joint pain as the body reacts to a foreign substance.

Stevens-Johnson syndrome: A rare, serious reaction causing painful blistering and peeling of the skin and the moist linings of the mouth, eyes, and other areas.

stomatitis: Soreness, swelling, or sores on the lining inside the mouth.

superinfection: A new, second infection that appears during treatment of the first one, often caused by germs the medicine does not kill.

suspension: A liquid holding fine drug particles that are mixed in but not fully dissolved, so it must be shaken before use.

teratogenic: Able to cause physical birth defects in a developing baby when a medicine is taken during pregnancy.

toxic epidermal necrolysis: A rare, life-threatening reaction in which large areas of the top layer of skin blister and peel away, like a severe burn.

transaminases: Liver enzymes measured in a blood test; higher-than-normal levels can be a sign that the liver is irritated or damaged.

urticaria: Raised, itchy welts on the skin, commonly called hives.

Use in Specific Populations: The label section describing how a medicine affects particular groups, such as pregnant people, children, or older adults.

Warnings and Precautions: The label section describing serious risks to know about and safety steps to follow while using a medicine.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

← 76420-0527-01 · Asclemed 76420-0530-06 · Asclemed →

For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.

Amoxicillin and Clavulanate Potassium 875 mg; 125 mg Tablet, Film Coated, 20-count

🆔 Identity & classification

🏷️ RxNorm drug class

🏭 Manufacturer & labeler

🩺 Clinical

Patient education

Supplement & herbal interactions

💊 What it looks like

🧪 Inactive Ingredients / Excipients

Inactive ingredient FAQ

💲 Pricing

🔁 Therapeutic equivalents

⏳ Availability & generic status

🔬 Reported adverse events (FAERS)

Top reported reactions

Age at onset

Reporter sex

Serious outcomes

📦 Packaging — all sizes for this product

🧭 About this NDC listing & data coverage

Questions about this listing

📄 Full prescribing information FDA SPL

12 CLINICAL PHARMACOLOGY

17 PATIENT COUNSELING INFORMATION

🔗 Related NDC lookups

💊 Related drugs in this class